Loading...

We've got a brand new version of Simply Wall St! Try it out

Vireo Health International

CNSX:VREO
Snowflake Description

Adequate balance sheet and fair value.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
VREO
CNSX
CA$167M
Market Cap
  1. Home
  2. CA
  3. Pharmaceuticals & Biotech
Company description

Vireo Health International Inc. operates in cannabis industry in the United States. The last earnings update was 24 days ago. More info.


Add to Portfolio Compare Print
  • Vireo Health International has significant price volatility in the past 3 months.
VREO Share Price and Events
7 Day Returns
-3.2%
CNSX:VREO
-5.9%
CA Pharmaceuticals
1.3%
CA Market
1 Year Returns
-
CNSX:VREO
-46.7%
CA Pharmaceuticals
-0.1%
CA Market
VREO Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Vireo Health International (VREO) -3.2% 12.6% -32.3% - - -
CA Pharmaceuticals -5.9% -3.4% -24.8% -46.7% 217.3% 286.4%
CA Market 1.3% 4.2% 1.6% -0.1% 8.4% 5.7%
1 Year Return vs Industry and Market
  • No trading data on VREO.
  • No trading data on VREO.
Price Volatility
Industry
5yr Volatility vs Market

VREO Value

 Is Vireo Health International undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
Here we compare the current share price of Vireo Health International to its discounted cash flow analysis.value.

The discounted cash flow value is simply looking at what the company is worth today, based on estimates of how much money it is expected to make in the future.
Raw Data

Below are the data sources, inputs and calculation used to determine the intrinsic value for Vireo Health International.

CNSX:VREO Discounted Cash Flow Data Sources
Data Point Source Value
Valuation Model 2 Stage Free Cash Flow to Equity
Levered Free Cash Flow Average of 3 Analyst Estimates (S&P Global) See below
Discount Rate (Cost of Equity) See below 7.1%
Perpetual Growth Rate 10-Year CA Government Bond Rate 1.9%

An important part of a discounted cash flow is the discount rate, below we explain how it has been calculated.

Calculation of Discount Rate/ Cost of Equity for CNSX:VREO
Data Point Calculation/ Source Result
Risk-Free Rate 10-Year CA Govt Bond Rate 1.9%
Equity Risk Premium S&P Global 6%
Pharmaceuticals Unlevered Beta Simply Wall St/ S&P Global 0.7
Re-levered Beta = Unlevered beta (1 + (1- tax rate) (Debt/Equity))
= 0.698 (1 + (1- 21%) (17.1%))
0.861
Levered Beta Levered Beta limited to 0.8 to 2.0
(practical range for a stable firm)
0.86
Discount Rate/ Cost of Equity = Cost of Equity = Risk Free Rate + (Levered Beta * Equity Risk Premium)
= 1.95% + (0.861 * 5.96%)
7.08%

Discounted Cash Flow Calculation for CNSX:VREO using 2 Stage Free Cash Flow to Equity Model

The calculations below outline how an intrinsic value for Vireo Health International is arrived at by discounting future cash flows to their present value using the 2 stage method. We try to start with analysts estimates of free cash flow, however if these are not available we use the most recent financial results. In the 1st stage we continue to grow the free cash flow over a 10 year period, with the growth rate trending towards the perpetual growth rate used in the 2nd stage. The 2nd stage assumes the company grows at a stable rate into perpetuity.

Note: Free cash flow to equity valuations ignore the company's cash or debt.

CNSX:VREO DCF 1st Stage: Next 10 year cash flow forecast
Levered FCF (USD, Millions) Source Present Value
Discounted (@ 7.08%)
2020 -20.54 Analyst x1 -19.18
2021 12.09 Analyst x1 10.54
2022 17.93 Est @ 48.28% 14.60
2023 24.09 Est @ 34.38% 18.32
2024 30.03 Est @ 24.65% 21.33
2025 35.39 Est @ 17.84% 23.47
2026 40.01 Est @ 13.07% 24.79
2027 43.91 Est @ 9.73% 25.40
2028 47.15 Est @ 7.4% 25.48
2029 49.87 Est @ 5.76% 25.17
Present value of next 10 years cash flows $169.00
CNSX:VREO DCF 2nd Stage: Terminal Value
Calculation Result
Terminal Value = FCF2029 × (1 + g) ÷ (Discount Rate – g)
= $49.87 × (1 + 1.95%) ÷ (7.08% – 1.95%)
$990.72
Present Value of Terminal Value = Terminal Value ÷ (1 + r)10
= $990.72 ÷ (1 + 7.08%)10
$499.93
CNSX:VREO Total Equity Value
Calculation Result
Total Equity Value = Present value of next 10 years cash flows + Terminal Value
= $169.00 + $499.93
$668.93
Equity Value per Share
(USD)
= Total value / Shares Outstanding
= $668.93 / 78.14
$8.56
CNSX:VREO Discount to Share Price
Calculation Result
Exchange Rate USD/CAD
(Reporting currency to currency of CNSX:VREO)
1.326
Value per Share
(CAD)
= Value per Share in USD x Exchange Rate (USD/CAD)
= $8.56 x 1.326
CA$11.35
Value per share (CAD) From above. CA$11.35
Current discount Discount to share price of CA$2.14
= -1 x (CA$2.14 - CA$11.35) / CA$11.35
81.2%

Learn more about our DCF calculations in Simply Wall St’s analysis model .

Current Discount
Amount off the current price Vireo Health International is available for.
Intrinsic value
>50%
Share price is CA$2.14 vs Future cash flow value of CA$11.35
Current Discount Checks
For Vireo Health International to be considered undervalued it must be available for at least 20% below the current price. Less than 40% is even better.
  • Vireo Health International's share price is below the future cash flow value, and at a moderate discount (> 20%).
  • Vireo Health International's share price is below the future cash flow value, and at a substantial discount (> 40%).
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Vireo Health International's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Vireo Health International's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
CNSX:VREO PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-06-30) in USD $-0.08
CNSX:VREO Share Price ** CNSX (2019-09-20) in CAD CA$2.14
CNSX:VREO Share Price converted to USD reporting currency Exchange rate (CAD/ USD) 0.754 $1.61
Canada Pharmaceuticals Industry PE Ratio Median Figure of 13 Publicly-Listed Pharmaceuticals Companies 15.3x
Canada Market PE Ratio Median Figure of 539 Publicly-Listed Companies 14.14x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Vireo Health International.

CNSX:VREO PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= CNSX:VREO Share Price ÷ EPS (both in USD)

= 1.61 ÷ -0.08

-19.44x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Vireo Health International is loss making, we can't compare its value to the CA Pharmaceuticals industry average.
  • Vireo Health International is loss making, we can't compare the value of its earnings to the Canada market.
Price based on expected Growth
Does Vireo Health International's expected growth come at a high price?
Raw Data
CNSX:VREO PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -19.44x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 3 Analysts
Not available
Canada Pharmaceuticals Industry PEG Ratio Median Figure of 7 Publicly-Listed Pharmaceuticals Companies 1.56x
Canada Market PEG Ratio Median Figure of 245 Publicly-Listed Companies 1.02x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Vireo Health International, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Vireo Health International's assets?
Raw Data
CNSX:VREO PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-06-30) in USD $1.44
CNSX:VREO Share Price * CNSX (2019-09-20) in CAD CA$2.14
CNSX:VREO Share Price converted to USD reporting currency Exchange rate (CAD/ USD) 0.754 $1.61
Canada Pharmaceuticals Industry PB Ratio Median Figure of 151 Publicly-Listed Pharmaceuticals Companies 2.36x
Canada Market PB Ratio Median Figure of 2,457 Publicly-Listed Companies 1.43x
CNSX:VREO PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= CNSX:VREO Share Price ÷ Book Value per Share (both in USD)

= 1.61 ÷ 1.44

1.12x

* Primary Listing of Vireo Health International.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Vireo Health International is good value based on assets compared to the CA Pharmaceuticals industry average.
X
Value checks
We assess Vireo Health International's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Pharmaceuticals industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Pharmaceuticals industry average (and greater than 0)? (1 check)
  5. Vireo Health International has a total score of 3/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

VREO Future Performance

 How is Vireo Health International expected to perform in the next 1 to 3 years based on estimates from 3 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
45.1%
Expected annual growth in revenue.
Earnings growth vs Low Risk Savings
Is Vireo Health International expected to grow at an attractive rate?
  • Unable to compare Vireo Health International's earnings growth to the low risk savings rate as no estimate data is available.
Growth vs Market Checks
  • Unable to compare Vireo Health International's earnings growth to the Canada market average as no estimate data is available.
  • Vireo Health International's revenue growth is expected to exceed the Canada market average.
Annual Growth Rates Comparison
Raw Data
CNSX:VREO Future Growth Rates Data Sources
Data Point Source Value (per year)
CNSX:VREO Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 3 Analysts 45.1%
Canada Pharmaceuticals Industry Earnings Growth Rate Market Cap Weighted Average 97.7%
Canada Pharmaceuticals Industry Revenue Growth Rate Market Cap Weighted Average 56.5%
Canada Market Earnings Growth Rate Market Cap Weighted Average 12.6%
Canada Market Revenue Growth Rate Market Cap Weighted Average 5.8%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
CNSX:VREO Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (2 months ago) See Below
Future Estimates Average of up to 3 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
CNSX:VREO Future Estimates Data
Date (Data in USD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2023-12-31 402 88 1
2022-12-31 360 64 1
2021-12-31 243 42 2
2020-12-31 151 24 3
2019-12-31 43 -14 2
2019-09-22
CNSX:VREO Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2019-06-30 24 -15 -6
2019-03-31 21 -10 -4
2018-12-31 18 -9 -3
2018-09-30 16 -6 -2
2017-12-31 11 -1 0
2016-12-31 4 -4 6

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Unable to determine if Vireo Health International is high growth as no earnings estimate data is available.
  • Vireo Health International's revenue is expected to grow significantly at over 20% yearly.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
CNSX:VREO Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (2 months ago) See Below
Future Estimates Average of up to 3 Analyst Estimates (S&P Global) See Below

All data from Vireo Health International Company Filings, last reported 2 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

CNSX:VREO Future Estimates Data
Date (Data in USD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2023-12-31
2022-12-31
2021-12-31
2020-12-31
2019-12-31
2019-09-22
CNSX:VREO Past Financials Data
Date (Data in USD Millions) EPS *
2019-06-30 -0.08
2019-03-31 -1.46
2018-12-31 -2.55
2018-09-30 -1.14
2017-12-31 -0.41
2016-12-31 5.58

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Vireo Health International will efficiently use shareholders’ funds in the future without estimates of Return on Equity.
X
Future performance checks
We assess Vireo Health International's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Canada market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Canada market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Vireo Health International has a total score of 2/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

VREO Past Performance

  How has Vireo Health International performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Vireo Health International's growth in the last year to its industry (Pharmaceuticals).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Vireo Health International does not make a profit and there is insufficient past data to establish if their 5 year on year earnings growth rate was positive.
  • Unable to compare Vireo Health International's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Vireo Health International's 1-year growth to the CA Pharmaceuticals industry average as it is not currently profitable.
Earnings and Revenue History
Vireo Health International's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Vireo Health International Company Filings, last reported 2 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

CNSX:VREO Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-06-30 23.52 -6.49 15.42
2019-03-31 20.56 -4.49 12.09
2018-12-31 18.46 -3.08 11.91
2018-09-30 16.10 -1.62 8.94
2017-12-31 10.87 -0.43 6.19
2016-12-31 4.26 5.80 3.96

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Vireo Health International has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if Vireo Health International has efficiently used its assets last year compared to the CA Pharmaceuticals industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Vireo Health International improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Vireo Health International's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Pharmaceuticals industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Vireo Health International has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

VREO Health

 How is Vireo Health International's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Vireo Health International's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Vireo Health International is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Vireo Health International's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Vireo Health International's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • High level of physical assets or inventory.
  • Debt is covered by short term assets, assets are 19.3x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Vireo Health International Company Filings, last reported 2 months ago.

CNSX:VREO Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2019-06-30 112.20 3.99 30.34
2019-03-31 109.28 1.43 40.40
2018-12-31 41.65 1.01 9.62
2018-09-30 38.48 1.01 15.21
2017-12-31 27.49 1.01 2.60
2016-12-31 28.11 0.03 2.09
  • Vireo Health International's level of debt (3.6%) compared to net worth is satisfactory (less than 40%).
  • Unable to establish if Vireo Health International's debt level has increased without past 5-year debt data.
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Vireo Health International has sufficient cash runway for 1.5 years based on current free cash flow.
  • Unable to confirm if Vireo Health International has at least 1 year of cash runway based on growing free cash flows without relevant data.
X
Financial health checks
We assess Vireo Health International's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Vireo Health International has a total score of 4/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

VREO Dividends

 What is Vireo Health International's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Vireo Health International dividends.
If you bought CA$2,000 of Vireo Health International shares you are expected to receive CA$0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Vireo Health International's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Vireo Health International's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
CNSX:VREO Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 3 Analyst Estimates (S&P Global) See Below
North America Pharmaceuticals Industry Average Dividend Yield Market Cap Weighted Average of 10 Stocks 2.8%
Canada Market Average Dividend Yield Market Cap Weighted Average of 334 Stocks 3.5%
Canada Minimum Threshold Dividend Yield 10th Percentile 1.1%
Canada Bottom 25% Dividend Yield 25th Percentile 2%
Canada Top 25% Dividend Yield 75th Percentile 5.8%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

CNSX:VREO Future Dividends Estimate Data
Date (Data in $) Dividend per Share (annual) Avg. No. Analysts
2023-12-31
2022-12-31
2021-12-31
2020-12-31
2019-12-31
2019-09-22

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Vireo Health International has not reported any payouts.
  • Unable to verify if Vireo Health International's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Vireo Health International's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Vireo Health International has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess Vireo Health International's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 1.1%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Vireo Health International afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Vireo Health International has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

VREO Management

 What is the CEO of Vireo Health International's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Kyle Kingsley
CEO Bio

Dr. Kyle Kingsley MD is the Founder, Chairman of the Board and CEO of Vireo Health International Inc. He served as the CEO of Minnesota Medical Solutions LLC until August 2018. Dr. Kingsley is a board-certified emergency medicine physician and founder of Vireo Health LLC, and Minnesota Medical Solutions LLC, a wholly-owned subsidiary of Vireo Health. Dr. Kingsley has been the Chairman of the Board at Minnesota Medical Solutions LLC since 2019. Dr. Kingsley has dedicated his work life to the refinement of the Vireo Health cannabis-derived medicine model, a system that focuses on patient care, sound medicine, excellent operations and vigorous science. Dr. Kingsley is co-author of the Medical Cannabis Primer for Healthcare Providers, which was written for physicians and other healthcare providers to improve cannabis-derived medicine education and understanding in the medical community.

CEO Compensation
  • Insufficient data for Kyle to compare compensation growth.
  • Insufficient data for Kyle to establish whether their remuneration is reasonable compared to companies of similar size in Canada.
Management Team Tenure

Average tenure of the Vireo Health International management team in years:

0.7
Average Tenure
  • The average tenure for the Vireo Health International management team is less than 2 years, this suggests a new team.
Management Team

Kyle Kingsley

TITLE
Founder

Amber Shimpa

TITLE
CFO & Director
TENURE
4.7 yrs

Ari Hoffnung

TITLE
COO & Director

Eric Greenbaum

TITLE
Chief Science Officer

Sam Gibbons

TITLE
Vice President of Investor Relations
TENURE
0.7 yrs

Michael Schroeder

TITLE
General Counsel & Chief Compliance Officer

Albe Zakes

TITLE
Vice President of Corporate Communications

Josh O’Neill

TITLE
Chief Business Development Officer

Jennie Leuzarder

TITLE
Vice President of Sales

Harris Rabin

TITLE
Chief Marketing Officer
TENURE
0.3 yrs
Board of Directors Tenure

Average tenure and age of the Vireo Health International board of directors in years:

0.3
Average Tenure
47
Average Age
  • The average tenure for the Vireo Health International board of directors is less than 3 years, this suggests a new board.
Board of Directors

Kyle Kingsley

TITLE
Founder

Amber Shimpa

TITLE
CFO & Director

Ari Hoffnung

TITLE
COO & Director

Amy Langer

TITLE
Director
AGE
47
TENURE
0.3 yrs

Chelsea Grayson

TITLE
Director
AGE
47
TENURE
0.3 yrs

Chad Martinson

TITLE
Director
AGE
46
TENURE
0.3 yrs

Judd Nordquist

TITLE
Director
AGE
49
TENURE
0.3 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month open market individual insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (CA$) Value (CA$)
26. Mar 19 Buy Chad Martinson Individual 19. Mar 19 19. Mar 19 13,820 CA$4.79 CA$66,170
X
Management checks
We assess Vireo Health International's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Vireo Health International has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

VREO News

Simply Wall St News

We Think Vireo Health International (CNSX:VREO) Can Stay On Top Of Its Debt

CNSX:VREO Historical Debt, August 15th 2019 A Look At Vireo Health International's Liabilities The latest balance sheet data shows that Vireo Health International had liabilities of US$8.75m due within a year, and liabilities of US$28.4m falling due after that. … This surplus suggests that Vireo Health International has a conservative balance sheet, and could probably eliminate its debt without much difficulty. … Vireo Health International may have net cash on the balance sheet, but it is still interesting to look at how well the business converts its earnings before interest and tax (EBIT) to free cash flow, because that will influence both its need for, and its capacity to manage debt.

Simply Wall St -

Did Vireo Health International Inc. (CNSX:VREO) Insiders Buy Up More Shares?

As Peter Lynch said, 'insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise.' Check out our latest analysis for Vireo Health International The Last 12 Months Of Insider Transactions At Vireo Health International Over the last year, we can see that the biggest insider purchase was by Director Chad Martinson for CA$66k worth of shares, at about CA$4.79 per share. … CNSX:VREO Recent Insider Trading, July 11th 2019 Insider Ownership of Vireo Health International For a common shareholder, it is worth checking how many shares are held by company insiders. … Our data suggests Vireo Health International insiders own 1.6% of the company, worth about CA$3.7m.

Simply Wall St -

VREO Company Info

Description

Vireo Health International Inc. operates in cannabis industry in the United States. It engages in the cultivation, production, and sale of medical cannabis products to company owned and third party dispensaries. The company sells and distributes a suite of products through dispensaries, home delivery, and wholesale channels. The company is headquartered in Minneapolis, Minnesota.

Details
Name: Vireo Health International Inc.
VREO
Exchange: CNSX
Founded:
CA$167,216,009
78,138,322
Website: http://www.vireohealth.com
Address: Vireo Health International Inc.
MoZaic East Building,
4th Floor,
Minneapolis,
Minnesota, 55408,
United States
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
CNSX VREO Subordinate Voting Shares Canadian National Stock Exchange CA CAD 20. Mar 2019
OTCPK VREO.F Subordinate Voting Shares Pink Sheets LLC US USD 20. Mar 2019
DB 0ZF1 Subordinate Voting Shares Deutsche Boerse AG DE EUR 20. Mar 2019
Number of employees
Current staff
Staff numbers
400
Vireo Health International employees.
Industry
Pharmaceuticals
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/09/22 00:54
End of day share price update: 2019/09/20 00:00
Last estimates confirmation: 2019/08/30
Last earnings filing: 2019/08/29
Last earnings reported: 2019/06/30
Last annual earnings reported: 2018/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.